Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Astra Zeneca, Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes and inadequate glycemic control, defined as A1C ≥ 6.6 and ≤ 9.5%
Stable dose of metformin AND/OR a sulfonylurea, for at least 4 weeks prior to the enrollment visit
Inadequate blood pressure (BP) control, defined as systolic BP (SBP) ≥ 130 and \< 165 mmHg, AND/OR diastolic BP (DBP) ≥ 80 and \< 105 mmHg
C-peptide ≥ 0.8 ng/mL
Estimated GFR by the Modification of Diet in Renal Disease (MDRD) formula \> 60 mL/min/1.73m² and \< 150 mL/min/1.73m²
Urine albumin:creatinine ratio (UACR) \< 300 mg/g
BMI ≤ 45.0 kg/m2
You may not be if
Administration of diuretics or other medication approved for the treatment of hypertension (with the exception of either ACEI or ARB), at any dose during the 12 weeks prior to the enrollment visit
History of adverse reaction to radio-contrast dye
Allergy or contraindication to use of thiazide diuretics
Aspartate Aminotransferase (AST) \> 3X Upper limit of normal (ULN)
Alanine aminotransferase (ALT) \> 3X ULN
Serum Total Bilirubin \> 1.5X ULN
Serum Creatinine (Scr) ≥ 1.50 mg/dL (133 μmol/l) for men; SCr ≥ 1.40 mg/dL (124 μmol/l) for women
Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncologic, endocrine, psychiatric, or rheumatic diseases
Clareo Health | Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
